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1.  Opinion N°4 from the Group of  ~dvisers on the Ethical implications 
of Biotechnology on Ethical Aspects of Gene Therapy OPINION OF THE GROUP OF ADVISERS 
ON ETffiCAL IMPLICATIONS OF BIOTECHNOLOGY 
OF THE EUROPEAN CO:MMISSION 
Date 13.12.94 
************************************************************************** 
THE ETHICAL IMPLICATIONS OF GENE THERAPY 
Reference :  Commission request for an opinion dated 23  September 1993 
Rapporteur :  Prof. Luis Archer 
************************************************************************** 
The  Group  of Advisers  on  Ethical  Implications  of Biotechnology  of the  European 
Commission : 
Having regard to the request of the Commission of 23  September  1993  for an 
Opinion  on gene therapy; 
Having regard to the Treaty  on European Union  and  in  particular articles  129, 
129 A and  Article F.2 of the Common Provisions; 
Having regard  to European Regulations in  particular the Council  Directives on 
genetically modified (micro) organisms 90/219/EEC and 90/220/EEC and relevant 
product legislation; 
Taking  account  of the  statements  expressed  by  the  European  institutions,  the 
Council  of Europe,  the  UNESCO  and  other  international  or  national  ethics 
committees; 
Having heard the report on  "Ethical Aspects of Gene Therapy" by the rapporteur 
Prof. Luis Archer; 
considering that·: 
1.1.  Scientists generally agree that somatic gene therapy is one of  the most promising 
ways of allowing to alleviate, to cure or to prevent a growing number of genetic 
as well  as acquired diseases, including cancer and even perhaps AIDS.  Somatic 
gene  therapy  has  indeed  recently  entered  the  clinical  setting  as  a  highly 
experimental therapeutic procedure.  An important and long lasting research effort 
is still required before routinely performed medical applications can be envisaged. 
1 1.2.  As  ~omatic gene  therapy  is  highly  experimental,  the  ethical  principles  to  be 
respected  are  at  the  very  least  all  those  applying  to  good  clinical  practice 
concerning research involving human subjects (namely, informed consent of the 
patients, with special care for children and incapacited persons, review of  research 
protocols  by  an  independant  and  multidisciplinary  body,  such  as  an  ethics 
committee,  proportionality of risks and  benefits,  confidentiality,  etc  ... ).  In this 
respect,  there  is,  concerning  gene  therapy,  a  tendency  in  many  countries  to 
reinforce the initial action of local  committees by  national  supervisory bodies. 
1.3.  Specific  regulations  concerning  genetically  modified  organisms  (directives 
90/219/EEC and  90/220/EEC as well  as product legislation) have been adopted 
to fulfill safety requirements.  These regulations do apply to certain research and 
development  aspects  relevant to gene therapy,  but not to clinical  trials in  the 
context of gene therapy. 
1.4.  At its present stage, gene therapy focusses on serious diseases for which there is 
no other effective available treatment.  In the future, therapeutic indications may 
be widened. 
1.5.  Somatic gene therapy has not only short term, but also individual and social long 
term consequences.  Its cost is at present high but could become much lower in 
the future.  In this respect, it should also be kept in mind that rare diseases are of 
little interest for  pharmaceutical  industry  compared to  more  frequent  diseases. 
Both these points raise the problem of equal access to treatment. 
1.6.  As  somatic  gene  therapy  applications  are  in  the  long  term  bound to  be  quite 
important, the use of new therapeutical products will be of great interest for the 
development of  European Union biotechnological industry.  Public control of the 
production  and  distribution  processes  is  already  exercised  in  some  European 
countries and will be influenced by the recently established European Agency for 
the Evaluation of Medicinal Products. 
1.7.  Germ line gene therapy, which implies the attempt to cure or prevent transmission 
to  future  generations  of  gene  defects  resulting  in  serious  diseases,  raises 
considerable and controversial ethical problems.  Although many discussions are 
already going on  in various fora,  the scientific basis and the technical feasibility 
of germ  line  gene  therapy  are  far  from  being  established.  The  possible 
transmission of  the modification to future generations raises specific philosophical 
questions.  Therefore, no proposal for clinical experimentation of germ line gene 
therapy on  humans is at present even  contemplated. 
1.8.  There  are  high  expectations  raised  by  the  prospect  of treating  or  preventing 
serious  and  widespread  diseases.  The  public  has  often  either  too  high 
expectations or needless concerns. 
2 The group submits to the European  Commission the following opinion : 
2.1.  Somatic gene therapy  should be encouraged at different necessary ·levels (basic 
research, clinical trials, biotechnology}, by supporting research actions (especially 
at  European  level  by  means  of the  Community  Research  Programmes  in 
Biomedicine and Health, involving also research on bioethics}, organizing training 
and  exchange  programmes  for  researchers  and  students,  and  by  any  other 
appropriate means: 
2.2.  The  ethical  evaluation  of somati·c  gene  therapy  protocols  requires  processes 
assuring quality, transparency and efficiency of  this evaluation without introducing 
any unnecessary delays to the treatment of patients.  In addition to local  review 
systems,  a national  supervisory  body is important to evaluate as  thoroughly  as 
possible this experimental technology. 
The harmonization and partial standardization of  all European evaluation processes 
could be helpful especially for research carried out at European level. 
2.3.  To  consider  the  specific  problems  linked  to  the  use  of genetically  modified 
organisms in the  context of gene therapy  implies a national  or even European 
control of  clinical trials.  Relevant regulations for this purpose could be elaborated 
at a European 1  evel. 
2.4.  Because of its present risk assessment,  somatic gene therapy should be restricted 
to serious diseases for which there is no other effective available treatment.  The 
widening  to  other  possible  therapeutical  indications  could  be  considered, 
indication  by  indication,  with  an  evaluation  of the  medical  as  well  as  ethical 
aspects. 
2.5.  Appropriate  measures  should  be  taken  to  assure  equal  access  to  gene  therapy 
within the European Union.  In addition, according to this equal access principle, 
a special status could be attributed at European level to orphan drugs and diseases 
as  already  done within the Biomedical  and Health Research Programme of the 
European Commission. 
2.6.  To  guarantee  transparency  and  to  fulfill  the  objectives  of  the  European 
construction  by  involving  the  citizens,  special  regulations  should  provide  for 
evaluation at European level of the risks and results of gene therapy technology. 
The conclusions of this evaluation must be regularly  published to allow public 
scrutiny and encourage public debate. 
2. T  Because of the important controversial  and  unprecedented  questions raised  by 
germline  therapy,  and  considering  the  actual  state  of the  art,  germ  line gene 
therapy on humans is not at the present time ethically acceptable. 
3 2.8.  It is of  vital importance that, simultaneously, public information and education are 
promoted,  so  that  the  public  gains  an  objective  and  correct  picture  of the 
possibilities and limitations of gene therapy and related developments.  The issue 
of gene therapy requires a didactic as well  as  a democratic approach,  involving 
a close participation of European citizens. 
In  accordance  with  its  terms  of reference,  the  Group  of Advisers  on  the  Ethical 
Implications of  Biotechnology hereby presents this Opinion to the European Commission. 
Signatures :  The Members 
The Chairman 
C/· 
4 2.  Avis  N°4  du  Groupe  de  Conseillers  pour  I'Etbique  de  Ia 
Biotechnologie relatif aux aspects etbiques de Ia therapie genique AVIS DU  GROUPE DE  CONSEILLERS 
POUR L'ETHIQUE DE  LA BIOTECHNOLOGIE 
DE  LA COMMISSION EUROPEENNE 
Date 13.12.94 
*********************************************************************** 
LES ASPECTS ETHIQUES DE LA TBERAPIE GENIQUE 
Reference : A  vis demande par Ia Commission le 23  septembre 1993 
Rapporteur : Prof. Luis Archer 
*********************************************************************** 
Le  Groupe  de  conseillers  pour  l'ethique  de  la  biotechnologie  de  la  Commission 
Europeenne 
vu Ia saisine de Ia Commission, du 23  septembre 1993, demandant un avis sur la 
therapie genique, 
vu le  Traite  sur l'Union  europeenne,  et notamment ses  articles  129,  129  A  et 
!'article F paragraphe 2 des Dispositions communes, 
vu Ia reglementation europeenne, en  particulier les Directives du Conseil sur les 
(micro  )organismes  genetiquement  modifies  90/219/CEE  et  90/220/CEE  et  la 
legislation relative a  la securite des produits, 
vu  les  differents  textes  emanant  des  institutions  europeennes,  du  Conseil  de 
!'Europe,  de  l'UNESCO  et  des  comites  d'ethique  nationaux  et  intemationaux, 
interessant la therapie genique, le  rapport de  M.  Luis Archer sur "Les aspects ethiques de Ia  therapie genique" 
entendu, 
Considerant les points suivants : 
1.1  Les  scientifiques  s'accordent,  en  general,  a  considerer  Ia  therapie  genique 
somatique comme l'une des voies les plus prometteuses pour soulager, guerir ou 
prevenir  un  nombre  croissant  de  maladies  non  seulement  genetiques  mais 
egalement acquises, y compris le cancer et peut-etre meme le SIDA. La therapie 
genique  somatique vient d'ailleurs  d'entrer en  phase clinique,  mais  en tant que 
procedure therapeutique encore tres experimentale. II faudra encore consentir un 
effort important et soutenu en  matiere de recherche avant de pouvoir l'envisager 
en tant que pratique medicale de routine. 
1.2  Compte tenu  du  fait  que  Ia  therapie genique n'en  est encore  qu'a un  stade tres 
experimental, les principes ethiques a respecter doivent englober au minimum tous 
ceux  regissant les  bonnes pratiques  cliniques  en  cas  d'experimentation  sur des 
sujets  humains  (a  savoir,  le  consentement  eclaire  des  patients,  en  tenant 
particulierement  compte  des  enfants  et  des  personnes  majeures  vulnerables, 
!'agrement  des  protocoles  de  recherche  par  un  organe  independant  et 
multidisciplinaire, tel qu'un comite d'ethique, Ia proportionnalite entre les risques 
et  les  benefices,  Ia  confidentialite  des  donnees  medicales,  etc.).  A  cet  egard, 
plusieurs  pays  ont  actuellement  tendance,  en  matiere  de  therapie  genique,  a 
renforcer  l'action  des  comites  locaux par !'intervention d'organes  nationaux  de 
control  e. 
2 1.3  Une reglementation specifique relative aux organismes genetiquement modifies 
(les  directives 90/219/CEE et  90/220/CEE  ainsi  que  la legislation  relative a la 
securite des  produits) a ete adoptee pour satisfaire aux exigences en  matiere de 
securite. Ces dispositions ne s'appliquent cependant qu'aux aspects de la therapie 
genique qui  sont lies  au  developpement et a la recherche,  mais non  aux  essais 
cliniques. 
1.4  Au  Stade  actuel,  la  therapie  genique  est  reservee  aux  maladies  graves  pour 
lesquelles  il  n'existe  pas  d'autre  traitement  efficace.  A l'avenir,  les  indications 
therapeutiques pourraient cependant etre etendues. 
1.5  La therapie genique somatique n'a pas seulement des consequences a court terme, 
mais  aussi  des  implications  a  long  terme,  pour  la  societe  comme  pour  les 
individus.  Si  son  cout  est  actuellement  encore  eleve,  il  pourrait  sensiblement 
diminuer a l'avenir. A cet egard, il convient de garder a l'esprit que, contrairement 
aux maladies les plus courantes, les maladies rares ne presentent guere d'interet 
pour l'industrie pharmaceutique.  Ces  deux considerations soulevent le probleme 
de l'egalite d'acces aux soins. 
· 1.6  Etant  donne  que  les  applications  de  la  therapie  genique  ne  manqueront  pas 
vraisemblablement de devenir importantes a  long terme, l'utilisation de nouveaux 
produits therapeutiques issus de  cette technique presentera un  grand interet pour 
le developpement de 1  'industrie de Ia biotechnologie dans l'Union europeenne. Le 
controle public des processus de production et de distribution de tel produits, deja 
assure dans certains pays europeens, sera influence par Ia toute recente "Agence 
europeenne pour I'  evaluation des  medicaments". 
3 1. 7  La therapie  genique  germinale,  qui  a  pour but  de  remedier  a  des  alterations 
genetiques provoquant des maladies graves de maniere a  eviter leur transmission 
aux  generations  futures,  souleve  des  questions  ethiques  tres  serieuses  et 
controversees.  Bien  qu'elle  suscite  deja  de  nombreux  debats  dans  differentes 
enceintes,  les  bases  scientifiques  et  la faisabilite  technique  de  cette  methode 
therapeutique  sont  loin  d'etre  etablies.  L'eventualite  de  Ia  transmission  a Ia 
descendance  des  modifications genetiques operees dans  le cadre de  Ia  therapie 
germinale pose des problemes philosophiques particuliers. C'est pourquoi, il n'est 
actuellement pas meme envisage de proposer une experimentation clinique de Ia 
therapie genique germinale concernant des etres humains. 
1.8  La  perspective  de  pouvotr  sotgner  ou  prevenir  des  maladies  graves  et  tres 
repandues  fait  naitre  d'immenses  espoirs.  Cependant,  l'opinion  publique  est 
souvent conduite a  avoir soit des espoirs excessifs, soit des craintes injustifiees. 
Le Groupe presente a  Ia  Commission europeenne l'avis suivant : 
2.1  Le  developpement  de  Ia  therapie  genique  somatique  doit  etre  encourage  aux 
differents  niveaux  requis  (recherche  fondamentale,  essais  cliniques,  industries 
biotechnologiques)  par la promotion  d'actions  de  recherche  (en  particulier  au 
niveau  enropeen  par le  biais des programmes communautaires de  recherche en 
biomedecine et sante, comprenant aussi Ia recherche en bioethique  ), I' organisation 
de programmes de formation et d'echange pour les chercheurs et les etudiants et 
par tout autre moyen approprie. 
4 2.2  L'evaluation  ethique  des  protocoles  de  therapie  genique  somatique  eXIge  des 
procedures garantissant Ia qualite, la transparence et l'efficacite de l'evaluation, en 
evitant  tous  delais  inutiles  dans  le  traitement  des  patients.  Outre  les  systemes 
d'evaluation  locaux, il  est important qu'il  existe un  organe de  controle national 
charge  d'evaluer  d~  fa~on  aussi  complete  que  possible  cette  technologie 
experimental  e. 
L'harmonisation  et,  dans  une  certaine mesure,  Ia  standardisation  des  processus 
d'evaluation  europeens  sembleraient  opportunes,  notamment  s'agissant  des 
recherches menees a  l'echelle europeenne. 
2.3  La  prise  en  compte  des  problemes  specifiques  lies a !'utilisation  d'organismes 
genetiquement modifies dans le contexte de Ia therapie -genique exige un controle 
national,  voire  europeen,  des  essais  cliniques.  Des  dispositions  particulieres 
devraient etre prises a  cet effet au niveau europeen. 
2.4  Compte  tenu  des  risques  qu'elle  presente  au  stade  actuel,  Ia  therapie  genique 
somatique devrait etre limitee aux maladies graves pour lesquelles il n'existe pas 
d'autre  traitement  efficace.  L'extension  a d'autres  indications  therapeutiques 
eventuelles devrait etre consideree, indication par indication, apres appreciation 
des aspects tant medicaux qu' ethiques d'une telle extension. 
2.5  Toutes mesures appropriees doivent etre prises pour garantir l'egalite d'acces a  Ia 
therapie genique  au  sein  de !'Union europeenne.  En  outre,  conformement a ce 
principe d'egalite d'acces, il  convient d'envisager de conferer un statut particulier, 
au niveau europeen, aux medicaments et aux maladies "orphelins", a  l'instar de ce 
qui  est  fait  dans  le  cadre  du  Programme  Communautaire  de  Recherche  en 
Biomedecine et Sante. 
5 2.6  Dans  le  souci  de  garantir  Ia  transparence  des  pratiques  et  conformement  aux 
objectifs de Ia construction europeenne d'assurer Ia participation des citoyens, il 
importe de prevoir des dispositions speciales en vue d'une evaluation des risques 
et  des  resultats  de  Ia  therapie genique au  niveau  europeen.  Les  conclusions de 
cette evaluation doivent etre publiees regulierement pour assurer }'information de 
!'opinion et favoriser le debat public. 
2. 7  En egard a  !'importance et au caractere controverse des questions sans precedent 
soulevees  par  Ia  therapie  genique  germinate  et  en  l'etat  des  connaissances 
scientifiques, Ia  therapie genique germinale sur l'homme n'est pas actuellement 
acceptable d'un point de vue ethique. 
2.8  II est essentiel de promouvoir simultanement !'information et l'education du public 
afin qu'il puisse avoir une vision exacte et objective des possibilites et des limites 
de Ia therapie genique et de ses developpements futurs. La question de Ia therapie 
genique doit  etre abordee en  suivant une  approche didactique et democratique, 
implicant une etroite participation des citoyens europeens. 
Conformement a  son mandat, le Groupe de conseillers pour l'ethique de Ia biotechnologie 
remet le present avis a  Ia Commission europeenne. 
Signatures :  Les membres 
Le preside 
6 3.  Report on ethical aspec1s of gene 1hempy from Prof. Archer GROUP OF  ADVISERS ON ETIDCAL IMPLICATIONS OF BIOTECHNOLOGY 
OF THE EUROPEAN COMMISSION 
Date: 13.12.94 
*********************************************************************** 
REPORT ON ETHICAL ASPECfS OF GENE THERAPY 
Reference : Commission request for an  opinion dated 23  September 1993. 
Rapporteur : Prof.  Luis Archer 
*********************************************************************** 
1.  DEFINIDONS 
Human gene therapy is  the  deliberate transfer of genetic material  into  a patient's cells 
. with the purpose of  curing or preventing a disease.  Removal of existing genes from cells 
is not yet technically feasible in  current clinical tests.  Only their addition is possible. 
Depending on the type of cells being the target of this gene transfer (somatic or germ-line 
cells), gene therapy is called somatic or germ-line gene therapy  respectively. 
Germ-line cells are spermatozoa or eggs and their precursor cells, as well as  cells of the 
early stages of the human embryo, before differentiation of the germ-line.  Somatic cells 
are all the other cells of the organism. 
It  is  assumed  that,  in  somatic  gene  therapy,  the  genetic  changes  introduced  are  not 
transmitted to the progeny, while they would be in the case of germ-line gene therapy. 
Somatic gene therapy is being practiced, as  experimental research in  human subjects, in 
a growing number of clinical centers in the world, including several European, countries. 
Germ-line  therapy  is  not  yet  available  in  a  clinically  useful  form,  but  its  ethical 
implications are being discussed. 
Enhancement genetic engineering (the transfer of a gene into  cells of a healthy  human 
being with  the purpose of improving desired characteristics such  as  height or memory, 
for instance) is  closely related to gene therapy and utilises the same technology. 
Enhancement  genetic  engineering  can  also  be  divided  into  somatic  and  germ-line 
engtneenng. 
1 ·. 
At present, somatic gene therapy techniques are considered ethical1y admissible only for 
the  treatme~t or prevention of serious diseases (see below, under 2.2),  the latter being 
defined as  diseases which cause significant suffering and premature death  (W.  French 
Anderson,  The J.  of Med.  and Phil.I4 ·:  681-693, 1989).  Consequently,  enhancement 
genetic engineering is presently excluded from the ethically admissible clinical trials and, 
for that reason, will not be considered in this Report.  If, in the future, clinical and ethical 
indications  arise  for  gene  therapy  of  minor  diseases  or  even  for  certain  health 
improvements, the matter should be discussed on a case by case basis.  Furthermore, a 
different and more philosophical discussion would then have to be opened in our society 
on the ethical acceptability or unacceptability of  certain kinds of  betterment of  the human 
nature. 
2 2.  E1HlCAL EVALUATION OF SOMATIC GENE THERAPY 
As  gene therapy  is  currently (and will stay  for a considerable time) in  an  experimental 
stage, there is a consensus that the ethical principles to be respected are those applying 
to the research on human subjects. 
Such principles, although sometimes formulated in slightly different forms, are essentially 
the same in all countries since the Helsinki Declaration (1964, 1975, 1983, 1989) and the 
Belmont Report (1978).  For our purposes they can be summarized in the following way: 
(1)  Benefits for  the  patient should  be  expected;  (2)  Disproportionate  risks  should be-
excluded;  (3) The dignity  or autonomy of the person should be respected;  (  4)  Justice 
should be attained.  We will follow this order in our discussion. 
2.1  Benefits 
For  an  increasing  number  of serious  and  lethal  diseases  (both  genetic  and  acquired 
diseases) gene therapy offers the prospect of  effective alleviation, cure or even prevention. 
In  addition  to  the adenosine deaminase (ADA) deficiency,  other genetic diseases have 
been the object of gene therapy protocols, namely familial  hypercholesterolemia, cystic 
fibros~s, Gaucher disease, glucocerebrosidase and hemophilia B.  Acquired diseases, like 
AIDS, cardiovascular diseases, and cancer are also being contemplated by gene therapy. 
As  matter  of fact,  cancer  is  the  disease  for  which  about  two  thirds of gene  therapy 
protocols have been designed.  Most of them attempt to interfere with the immune system 
of cancer bearing patients by  transferring to  tumor infiltrating lymphocites (TIL)  or to 
tumor cells genes coding for cytokines or for foreign antigens.  This strategy is becoming 
known as "vaccination".  In other attempts, a "suicide" gene is transferred to tumor cells 
with the objective of rendering them sensitive to  a drug  which is  otherwise non-toxic. 
Other protocols transfer the  multidrug  resistance gene to  hematopoietic cells  with  the 
purpose of making  them resistant to high dose chemotherapy. 
Initially, somatic gene therapy was always performed ex vivo. This meansthat target cells 
were removed ftom the patient, grown in culture in vitro, genetically modified by the use 
of an appropriate vector, and then harvested and finally reimplanted in the same patient. 
More  recently  an  in  vivo  strategy  started  being  developed  which  involves  direct 
administration  of the  gene-carrying  vector  into  the  patient's organism.  As  this  latter 
strategy tends to be used more progressively, each of  the individual clinical trials will be 
less  dependent  on  sophisticated high-technology,  and the  ethical  use  of somatic  gene 
therapy  will  become much  easier and  more widespread.  It will  then  have a profound 
impact on  medicine. 
Disease prevention can  be obtained by  the appropriate gene transfer to  individuals who 
show by pre-symptomatic genetic tests, the presence of a gene defect·causing a late-onset 
disease.  We could also call disease prevention the appropriate gene transfer to individuals 
who showed, by  genetic testing, predispositions for a given disease,  like breast cancer, 
ischemic heart  disease (through low level  of LDL receptor molecules in  the liver) and 
others. 
3 In  addition, gene therapy may develop, in  the future, into a sophisticated drug delivery 
system.  Instead of giving a certain agent by repeated or even  daily injections, it might 
be preferable to administer it by a one-time insertion of  the patient's own gene-engineered 
cells. 
The benefits of somatic gene therapy for alleviation, cure, or prevention of genetic and 
acquired diseases are, therefore, very promising.  These benefits are of special relevance 
when alternative therapies for a given disease are poor or inexistent. 
2.2  Risks 
In order to  evaluate risks, sufficient scientific knowledge on the physiopathology of the 
disease and on the molecular biology of the gene concerned, as well as of its vector, are 
required.  This  knowledge,  together with  animal  experimentation  (including that non-
human primates), should show whether or not (i) the therapeutic gene is expected to be 
inserted  at  the  right  place  in  the  target  cells  and  to  remain  there  long  enough  to  be 
effective,  (ii)  the  introduced  gene  is  appropriately  regulated,  producing  acceptable 
amounts of the product and (iii) there are no secondary effects. 
This latter requirement is, presently, very difficult to assess.  As  mentioned by  the U.K. 
"Report on the Ethics of Gene Therapy" (Clothier Report),. the questions of safety  "are 
heightened  by  the  possibility  of inadvertent  and  unpredictable  consequences  of gene 
therapy to the patient, and the possible long term consequences" (8.8).  For example, the 
much used retroviral vectors integrate in points at random of the genome.  If integration 
takes place in certain points, it may activate an oncogene, or inactivate an anti-oncogene, 
or block an  essential  gene
1
.  It is  important that the public is  aware of these potential 
risks,  so  that the review and  oversight of  gene therapy protocols  do  not become too 
relaxed  and  when  the first serious problems come,  the public does  not force  a halt or 
significant slowdown of gene therapy research, which should, nevertheless, continue and 
be encouraged to the benefit of so  many patients. 
It is, in part, in order to outweigh the above mentioned risks and uncertainties that most 
regulations prescribe that the diseases initially selected for gene therapy should be serious, 
and lack effective alternative treatments
2
. 
2 
Even the optimistic W.  French Anderson agrees that "over time, problems will arise. 
It is even possible that our worst fears will be realized and a patient develops a 
leukemia, a solid tumor, or some other serious pathology as  a result of the gene 
transfer" (Human Gene Therapy, 2:194, 1991). 
The Clothier Report speaks of "disorder which is  life threatening, or causes serious 
handicap, and for which treatment is unavailable or unsatisfactory" (p.25 ). 
The Guidelines of the European Medical Research Council mentions "diseases which 
are invariably fatal  or severely disabling and for which current therapies (  ... ) are not 
always feasible or carry a high level of risk" (Lancet June 4, 1988, p.  1271). 
The 1993  Opinion of the French National Ethics  Committee restricts somatic gene 
therapy to  "disorders for which no  effective treatment is  available and for \vhich the 
prognosis is sufficiently serious to warrant the risks entailed in the application of what 
is, as  yet basically an experimental form  of treatment. 
4 The  Medical  Research  Council  Guidelines  state  (p.31)  that only  once  the  trials  with 
devastating diseases have proven to be effective and safe, should other less burdensome 
diseases be considered, such as  hemophilia and PKU, for  which  alternative treatments 
exist. 
2.3  The dignity of dle peBon 
In  first  the  place,  the  interests  of the  patient's health  should  always  prevail  over the 
research interests. 
The rights to confidentiality and privacy, in their· conventional forms, also belong to the 
duty of respecting human dignity. 
In addition, informed consent of the patient should be obtained, noting that, due to  the 
declared uncertainty  implicit in  experimental treatments, the standard of disclosure for 
patient involvement and  authorization should be higher than  the standard required for 
conventional treatments.  The Clothier Report from the UK further requires that patient~ 
receive advice from  an  independent source,  unrelated to the research team.  The  1993 
Opinion  from  the  French  National  Ethics  Committee  develops  the  concept  that 
information  supplied  to  the  families  involved  and  to  the  public  be  "·as  objective, 
restrained, measured and realistic as possible". 
As many gene therapy trials involve children, the informed consent given by their parents 
or guardians should  assume  a truly  vicarious  form  : they  are supposed to  decide  not 
according to their interests but according to what is presumed that the child would decide 
if he or she would be already competent.  A specially difficult situation is that of foetal 
gene therapy, recommended cases of some genetic disorders which lead to  irreversible 
and cumulative effects before birth.  This issue is complicated by the conflicting views 
on the status of the embryo and foetus. 
2.4  Justice 
Access  to  gene  therapy  of every  potential  candidate  is  an  important  ethical  concern. 
Because gene therapy was initially dealing with a few,  very rare diseases, the problem 
was not acute.  as soon as it is extended to other and more common diseases, the problem 
of fair selection of patients will have to be faced.  It should be prescribed that the criteria 
used for  selection of patients is  included in  the proposal  to  be reviewed by  the ethics 
committee.  A  fair  selection  of the  diseases  to  be treated  should  also  be  considered. 
Special care should be taken of "orphan diseases" '(those affecting few patients) which are 
other given great social support but are of little or no interest to the medicinal industry. 
5 A second problem of justice refers to  the distribution of resources for health  care.  In 
contrast  to  a  more  utilitarian  view  in  the  US,  most  european  countries  defend  that 
everybody's right to  health  care is  equal.  However, the debates on  resource allocation 
have  shown  that,  due  to  the  fast  increasing  number of new biomedical  technologies, 
scarcity  of resources  is  becoming  evident  and  choices  in  health  care  are  therefore 
inevitable.  In this same context, socialized medicine, which is traditional in Europe, has 
recently given some place to forms of medical privatization.  These problems of choices 
in health care will soon affect gene therapy, specially because this new technology is,  at 
the moment, still very expensive.  Criteria for priorities in health care have to be globally 
studied, discusses and established
3 
A third problem of  justice deals with the distribution of  gene therapy centers among the 
different countries.  It would not seem fair that the benefits of this new technology were 
restricted to  industrialized countries.  It would be advisable to  develop a policy for the 
promotion of gene therapy applications in  developing countries. 
An example of such a study is  the report "Choices in  Health Care" ("A  Report from 
the Dutch Governmental Committee on Choices in Health Care". Zoetermer, The 
Netherlands, 1992) where four criteria are given to  inclusion of a given technology in 
the "basic package", namely a.  Is  it  necessary care, from  the community point of 
view ? : b.  Is  it  demonstrated to  be effective ?  ~  c.  Is  it efficient ? : d.  Can it be left to 
individual responsibility ?" 
6 3.  ETillCAL  REVIEW  OF  SOMA TIC  GENE  lliERAPY  PROTOCOLS  AND 
PRODUCfS 
3.1  Review of protocols 
Any  somatic  gene  therapy  protocol  must be assessed  as  to  the  ethical  aspects.  The 
natural  places for  such  assessment are the local  research ethics committees.  They  are 
supposed  to  be  advisory  bodies,  leaving  the  responsibility  of any  accident  with  the 
medical team.  However, th_ere  is a tendency in several European countries, as well as in 
the  United States, to look for a reenforcement of the action of the local committees by 
one or more national supervisory bodies. 
In  the  United  States,  the  biological  safety  of the  gene  therapy  research  protocols  is 
reviewed by  a local  committee (Institutional  Biosafety  Committee, IBC) and  by  two 
federal  agencies : NIH, through its Recombinant DNA Advisory Committee (RAC) and 
the Food and Drug Administration (FDA).  However, only NIH-funded investigators or 
investigators  who  work  in  institutions receiving NIH funding  are  required to  undergo 
RAC review.  On the contrary, FDA review is mandatory for all investigators, regardless 
of the funding source. 
·In the United Kingdom, the Clothier Report (1992) recommended the establishment of 
an  "expert  supervisory  body",  acting  in  coordination  with  the  local  research  ethics 
committees,  with  tasks  of advising,  receiving  proposals  and  recommending  them  for 
approval,  monitoring,  oversight  and  providing  advice  to  Health  Ministers.  The 
recommendations of the Clothier Report were accepted by the Government and a "Gene 
Therapy Advisory Committee" was set up,  as a non-statutory advisory body to oversee 
_ the conduct of gene therapy in the UK. 
In France, the National Ethics Committee declared, in its 1993 Opinion that somatic gene 
therapy protocols fall under the socalled "Loi Huriet (1988)" as well as under the law of 
13  july  1992  on  the  use  of genetically  modified  organisms.  This  means  that  the 
researcher must approach, in  addition to his local research ethics committee, two other 
committees.  In  addition,  "it  is  imperative that  the  results  of these  trials  are  closely 
monitored by  a technically and scientifically competent assessment committee as well as 
by the Comite Consultatif National d'Ethique pour les Sciences de Ia Vie et de Ia Sante" 
(CCNE, Avis de 1993). 
In the Netherlands, at least for the first submitted protocols ( 1991-1992), approval by the 
local  research ethi.cs  committee was followed by a positive advice from  the VCOGEM 
Committee (concerned with  introduction into the environment of genetically  modified 
organisms)  and  a  decisive  opinion  from  the  central  "Core  Committee  on  Medical 
Research Ethics" (KEMO). 
In  Italy, the protocols were approved by the local research ethics committee and by the 
Italian Committee for Biosafety.  The Italian National Committee on Bioethics published, 
in  1991, a report on  "Therapia genica"  which describes the conditions for approval  of 
gene therapy  protocols and suggests the creation  of an  authority  uncharged of listing 
diseases  which  could  candidate  for  gene  therapy,  developing  criteria,  and  collecting 
information on gene therapy  research. 
7 In  Germany,  the  "Central  Committee  for  the  maintenance  of moral  principles  in 
reproductive medicine, embryo research, and gene therapy" works in  close collaboration 
with the locat institutional review boards, having an advisory role on the definition of  the 
criteria for evaluation, but leaving the final  decisions to the local ethics committees. 
The 1988 Guidelines from the European Medical Research Councils recommend that "a 
national  body  should  consider  all  proposals  for human  gene  therapy  and  ensure  the 
application of agreed national guidelines.  Early trials should be monitored by a central 
body". 
Since  1989,  the  Council  of  Europe  has  recommended  "national  or  regional 
multidisciplinary bodies"  with  tasks of informing, guiding, monitoring, and evaluating 
results.  At the First Round Table of Ethics Committees (Madrid, 1992), the Council of 
Europe  suggested  that  national  ethics  committees  be  consulted  as  an  instance 
complementary  to  the  local  ethics  committees,  in  regard  to  formulation  of standards, 
support, oversight, and evaluation
4
. 
Directives 90/219/EEC and 90/220/EEC from the European Union apply to certain phases 
of the gene therapy protocols, but do not cover, for instance, the clinical trials.  These are 
regulated, in  some European countries, by specific legislation.  It might be desirable to 
have, on this, a legal  document at European level. 
An  important ethical  requirement for  the whole net of control  mechanisms is  that,  in 
addition  to  the  quality  of the  ethical  argument,  they  are  efficient  and  do  not  cause 
unnecessary delays.  Illnesses wi11  not wait for a more convenient time and the patients 
need any help that can be given to them now.  For such efficiency, the harmonization and 
partial standardization of all  European evaluation processes might be helpful. 
Another important ethical  requirement is  the transparency of the  evaluation processes. 
They should be regularly published, giving to the public an objective information on the 
scientific  and  ethical  aspects  of gene  therapy  developments,  and  promoting the  close 
participation  of European  citizens  in  the  democratic  construction  of  our  sctence, 
technology, and  ethics. 
3.2  Review of gene dlerapy products 
It is expected that, within a 3-5 years period, products for gene therapy are ready to come 
on the market.  The gene therapy market is expected to be, in the near future, very large 
and the economic impact on biomedical  equipment and gene therapy consumables will 
be considerable.  It is important, therefore, that the manufacturing, commercialization, and 
distribution of gene therapy products are appropriately regulated. 
4  For a more detailed description of national and  international evaluation instances. see 
M.A.M. de Wachter "Experimental (somatic) Gene Therapy : Ethical Concerns and 
Control", Institute for Bioethics, Maastricht, 1993. 
8 The commercially manufactured products will  be covered by  Community legislation and 
evaluated on the basis of quality, safety and efficacy, criteria laid down in the legislation 
for biotechnological products.  In addition, the code of "Good Clinical Practice for Trials 
on  Medicinal  Products in  the European  Community"  has to  be  observed.  .  This  code 
includes the requirements for informed consent of the subject taking part in the trial and 
for  the  review  of  the  local,  pluridisciplinary  and  independent  ethics  committee. 
Additional guidelines for specific quality and safety requir.ements in the manufacture and 
control of products for gene therapy will  be available in  1995. 
Products  for  gene  therapy  will  also  need  a  marketing  authorization  given  by  the · 
centralized procedure of the European Agency for the Evaluation of Medicinal Products. 
This Agency will  start work in London on January  1st  1995.  Through this procedure, 
patients from all  12 member States will have equal access to medical products, since the 
products will  be sold in  all  States of the  Union.  Manufacturers will  be assisted  in  the 
preparation  of the  applications  for  marketing  authorization  by  the  Committee  for 
Proprietary Medicinal Products (CPMP).  The competent authorities of  the member States 
are represented in  the CPMP. 
9 4.  EmiCAL EVALUATION OF GERM-LINE GENE THERAPY 
The present state of knowledge in germ-line gene therapy can be described as follows : 
a)  there is  no  sufficient experience and  monitoring of somatic gene  therapy  as  to 
clearly  _establish  the  safety  and  effectiveness of its  use  and,  much  less,  of its 
extension to  the self-perpetuating germ-line; 
b)  they  are  no  sufficient  animal  studies  on  germ-line  gene  therapy  applicable  to 
humans; 
c)  there is not yet any  clinically useful and clearly proposed protocol for germ-line 
gene therapy,  defining, namely, the vectors to  be used  and the  potential  target 
cells (spermatogonia ?,  eggs ?,  embryos ?). 
With such scientific uncertainties, some contend that a ethical evaluation is  impossible. 
Nevertheless,  we  will  attempt  to  apply  to  germ-line  gene  therapy  the  same  ethical 
principals used for somatic gene therapy. 
4.1  Benefits 
Some argue that germ-line gene therapy will be useless.  In fact, for the vast majority of 
the cases, only one of the parents is carrying the genetic defect.  In such cases, it would 
be  easier  and  safer  to  select  healthy  embryos,  by  preimplantation  diagnosis,  than  to 
perform gene therapy on those which carry the defect.  Only in the highly exceptional and 
unlikely cases of embryos produced by two individuals both being recessive homozygous 
for  the same  defect  would  gene therapy  be  useful,  since  all  embryos  would  then  be 
affected.  It can be answered, however, that other and more frequent cases  in  genetics 
could be mentioned where preimplantation diagnosis is of  no help
5
.  The same applies to 
diseases  due  to  mitochondrial  gene defects
6
.  In addition, it should be  mentioned that 
embryos are not the only target of germ-line gene therapy.  The European Patent Office 
received  recently  a patent request,  coming  from  two  researchers of the  University  of 
Pennsylvania,  which  deals  with  gene  therapy  of spermatogonia.  Although  the  main 
applications  are  in  the  field  of veterinary,  the  patent  request  explicitly  mentions  its 
. applicability to humans (New Scientist 9,  April  1994).  Gene therapy of spermatogonia 
might be the on!y possible option for those who have serious ethical objections against 
preimplantation diagnosis and destruction of pre-embryos. 
6 
This is  the case of "parents who do not wish to have heterozygous children in order to 
spare them  the difficult decisions they would have when they in tum came to  have 
children.  This situation is  already becoming more frequent in genetics.  It happens 
when one parent is homozygous recessive and the other heterozygous for the same 
disease; in this case 50%) of the eggs will be affected, 50% will be heterozygous and 
preimplantation diagnosis will be unable to identify a non-heterozygous embryo", 
Pierre M.  Lehn, Scientific Aspects of Gene Therapy, a report to  be published, p.  35, 
1994. 
For diseases due to  defects in the mitochondrial genome~ different conditions apply. 
Peimplantation diagnosis is  not an option, and "germ-line gene therapy" would consist 
of the replacement of the entire mitochondrial population rather than insertion of DNA 
into  an existing genome.  This approach would not carry the risks inherent in 
recombinant DNA techniques. 
10 Considering that germ-line gene therapy is the only technique able to perform a 
genetic change in all the cells of  an individual, the XXIVth Round Table from the 
Council for International Organizations of Medical Sciences declared in Inuyama 
{1990),  that  germ-line  therapy  might  be  "the  only  means  of treating  certain 
conditions, so continued discussion of both its technical and its ethical aspects is 
therefore essential".  A Report of the same Meeting concludes : "The option of 
germ cell  gene therapy must not be prematurely foreclosed.  It may  some day 
offer clinical benefits attainable in no other way.  Science has confounded many 
predictions about w~at is technically possible and what is not.  Germ cell therapy 
might eventually permit more effective prevention of genetic disease, rather than 
treatment of its effects". 
Sometimes, germ-line gene therapy is even presented as  a  medical  imperative. 
The  moral  mandate of medicine  is  to  cure,  to  care,  and  to  prevent  diseases, 
alleviating suffering as much as possible.  Considering that such possibility may 
be expanded by this self-perpetuating therapy, medicine has a prima facie moral 
duty to pursue and employ germ-line gene therapy as  soon as it is safe
7
. 
Another benefit is its prophylactic efficiency.  By preventing transmission at "the 
affected genes, germ-line gene therapy would dispense with the need to perform 
costly  and  risky  somatic  gene  therapy  in  multiple  subjects  of  successive 
generations. 
4.2  Risks 
The description of the present state of knowledge given above (under 4) shows that the 
conditions for risk evaluation, required under 2.2, are far from being met.  The situation 
will persist that way for quite a number of years. 
It is  clear that without risk  evaluation, specially  considering that any  negative effects 
would  be  indefinitely  perpetuated,  to  start now  any  attempt of germ-line  therapy  in 
humans would  be severely  unethical  and  should be forbidden.  This  seems to  be an 
unanimous position of all statements produced on the matter by a variety of institutions
8
. 
"Keeping diabetics alive with insulin, which increases the propagation of an  inherited 
disease~ seems justified only if one is willing to do genetic engineering to  remove 
diabetes from  the germ-line and  thus to  save the anguish and  cost to  millions of 
diabetics" (Daniel Kosh1and, CQ Researcher 1 (23) : 793,  1991) 
It is true that the Spanish law on techniques of assisted reproduction (Act 3511988) in 
principle authorizes therapy on in vitro pre-embryos "to treat an  illness or prevent its 
transmission" (13.1) "if influence is  not being exercised on non-pathological hereditary 
characteristics" (13.3.d).  However, the conditions then set for this authorization are 
precisely those which are not yet met by  science.  Therefore, the Spanish law does not 
seem  to  make an exception to  the consensual interim prohibition of germ-line gene 
therapy. 
11 The differences of opinion begin when we ask whether this is the only reason to oppose 
germ-line therapy.  For some, the present uncertainty on  risks and  benefits is  the only 
reason for prohibition or non authorization
9
,  while, for others (to be mentioned below), 
additional basic and non  circumstantial objections exist, which lead to the condemnation 
of germ-line therapy not only in the present situation but per se, even if  one day sufficient 
safety guaranties were at hand
10 
4.3  The  dignity of the person 
Let  us  assume  that  a  day  comes  when  sufficient  data  on  germ-line  gene  therapy 
accumulated  (including  experimentation  in  non-human  primates  treated  by  the  same 
vectors and procedures to be used in humans) which made possible an accurate evaluation 
of risks as  well  as  of side-effects and these were shown to be negligible.  How would 
then germ-line therapy be ethically evaluated ? 
9 
10 
The Resolution of the European Parliament adopted on 16 March 1989 states that 
any, even partial, modification in the genetic information of germ-cells represents 
an  unacceptable  and  unjustifiable  distortion  of human  identity.  The Working 
Group on Ethical, Social and Legal Aspects of the Human Genome Analysis from 
the  European  Commission,  in  its  1991  Report,  gives,  as  two  of the  causes  of 
concern, the changes in the human gene pool and possible "eugenic" implications. 
The Report " Terapia genica"  from  the Italian national committee of ethics also 
evokes,- against germ-line therapy, the  "intangibility of the genetic pool".  It is 
known, however, that, in a variety of ways, we have been constantly changing the 
human gene pool without incurring the tremendous risks of eugenics.  In addition, 
from  the  analysis of these statements  we  conclude that they  address germ-line 
therapy but really have in  mind germ-line enhancement. 
In  addition to  positions already mentioned, we can add, as  typical examples, the 
Spanish law on techniques of assisted reproduction (Act 35/l988), the Clothier Report, 
the 1990 and  1993  Opinions from  the French National Ethics  Committee~ the Report 
from  the Dutch Health Council's Commission on Heredity.  Science and Society, the 
Declaration of Bilbao ( 1993) and the Draft Convention on Bioethics from  the Council 
of Europe.  In  its Article 16, the Draft Convention states "An intervention on the 
human genome may only be undertaken for preventive, therapeutic or diagnostic 
purposes and  as  long as  the aim  is  not to interfere with the germ  cell line".  The only 
reason given in the Explanatory Memorandum for the last part of this Article is  that, 
"at the present stage of scientific knowledge, it was impossible to  know all  the effects 
that these interventions might have on following generations". 
Along the same lines, the President of the UNESCO International Bioethics 
Committee made the following statement in her 1993  Report : "An agreement (albeit 
provisional) seems to have been reached on the need to  prohibit recourse to  this form 
of therapy (germ -line) as  long as  the scientific data enabling its control are unavailable 
and, consequently, as  long as  it comprises risks of uncontrolled alteration of the 
human genetic capital.  The chapter on the debate surrounding germinal therapy is  no 
doubt unfinished.  There is  no consensus about whether we should oppose it in the 
name of the inviolability or the integrity of the human race, or limit ourselves to  the 
idea of a simple moratorium". 
12 A frequent objection uses the slippery slope argument : germ-line gene therapy 
would  open  the  door  to  attempts  at  germ-line  enhancement  of human  traits, 
leading us to impose on future generations certain characteristics according to our 
capricious  choices,  what certainly  is  an  offensive instrumentalization  of future 
human beings.  The safest course in order to prevent such abuses  would be the 
unconditional prohibition of  germ-line therapy.  It can be answered, however, that 
the same argument has been used in the past, by Jeremy Rifkin and his followers, 
against somatic gene therapy and it was nether succesful nor correct. Somatic gene 
therapy is being carried on with societal approval and considerable benefits, while· 
no attempts are kno.wn of somatic enhancement engineering. 
Recommendation 934 (1982) from the Council of  Europe states that "the rights 
to life and to human dignity (  ... ) imply the right to inherit a genetic pattern which 
has not been artificially changed" but adds that the recognition of this right "must 
not  impede development of the  therapeutic  applications of genetic  engineering 
(gene  therapyf'.  Recommendations  1046  (1986)  and  1100  (1989)  from  the 
Council  of Europe develop the same concept.  Since these documents specially 
focus  on the protection of the individuals against non- therapeutic applications, 
asking even for a "list of serious diseases which may properly (  ... ) be treated by 
gene  therapy"  we  conclude  that  these  Recommendations  are  frontally  against 
germ-line enhancemet;1t engineering but not against germ-line gene therapy.  We 
might only regret that the issue is so phrased that the right to  a healthy genome 
is not recognized as a basic principle, but only as an exception of the questionable 
right  to  an  untouched  genome.  It is  not  clear  why  hazards  of nature  should 
necessarily be better than achievements of science. 
Some  members  of the  German  Bundestag  Commission  of Inquiry  of genetic 
engineering,  which  published  the  Report  "Risks  and  Chances  of  Gene 
Technologies" (1987) expressed the view that any changing of  the germ-line, even 
for the correction of defects, is an  act against nature.  The same Report states : 
"The humanity of human beings rests at its core on natural development" and "the 
dignity  of human  beings  is  based  essentially  on  their  being  born  and  on  the 
naturalness  of their  origins"  ( 187).  This  view  overlooks  the  importance  of 
artificial components in our lives and activities.  We are artificial beings by  our 
very nature.  The human intelligence and the consequent capability of innovation 
and creativity also belong to nature. 
Assuming that germ-line gene therapy will be performed in in vitro embryos, the 
same  "Risks  and  Chances of Gene Technologies"  Report  states  that  germ-line 
therapy  techniques  will  imply  the  destruction  of many  embryos,  thus  making 
human life only a means to  an end.  On this point, there is certainly an unsolved 
world  controversy.  But, as  we  have already noticed, embryos are not the only 
target of germ-line gene therapy. 
A common  objection is  the lack  of consent from  future  generations.  Multiple 
human  generations  would  be  placed  in  the  situation  of unconsenting  research 
subjects.  This objection fully holds for germ-line enhancement engineering.  But 
for the case of germ-line gene therapy of very serious diseases we can reply  that 
such  consent is  presumed.  According to the above mentioned Inuyama Report 
(1990),  "descendants  of those  so  treated  would  still  agree  with  the  decision 
generations later". 
13 4.4  Justice 
Those  who  fear  that  germ-line  gene  therapy  slips  into  enhancement  genetic 
engineering of human traits, objec't that this would exacerbate problems of social 
discrimination  based  on  those  traits.  We already  took  position  (under  4.3)  in 
regard to  this slippery slope argument. 
Others  have  objected  :  on  the  basis  of how  to  prevent  social  discrimination 
favoring elites through germ-line therapy ? But considering that there will be, at 
least initially, a limited number of situations which meet the clinical indications 
for  this therapy, the problem will  not be unsurmountable.  In addition,  abuses 
should not be impeditive of fair uses. 
In  conclusion, no decisive arguments could be found to prove, a priori, that any kind of 
germ-line gene therapy  would necessarily  affect human  dignity  and justice.  The only 
solid  reasons  to  oppose  germ-line  gene  therapy  for  the  time  being  are  the  scientific 
unc-ertainties  which  prevent  us  from  evaluating  benefits  and  risks.  As  long  as  this 
situation persists, any attempt of performing germ-line gene therapy in human subjects 
would be irresponsible and should be forbidden.  As soon as the situation is scientifically 
clarified, it will  have to  be ethically reevaluated. 
The Rapporteur 
Luis Archer 
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THE  GROUP  OF  ADVISERS  ON  THE  ETHICAL 
IMPLICATIONS OF BIOTECHNOLOGY GOES PUBLIC WITH . 
ITS ADVICE TO THE EUROPEAN COMMISSION ON GENE 
THERAPY  . 
The remarkable advances in scientific and medical research in the second half of  the 
20th century have paved the way for the development for biotechnology and genetic 
engineering, covering a wide range of processes whose applications- ranging from 
agriculture to industry and from the environment to health - are of  concern to various 
instances in the European Community. 
This is  why,  in  December 1993, the White Paper on  growth, competitiveness and  . 
employment ranked  biotechnology among Europe's priority policy areas. 
Although  the  rise  of biotechnology  has  given  rise  to  expectations  - not to  say 
enthusiasm - there is also some apprehension. The key point must be to control the 
scientific advances so as to enhance the quality of life and the standard of living of 
the people of Europe and to secure for them the highest possible standard of health 
in  keeping with the values of our society. 
The Commission is directly concerned with this important debate, as evidenced by 
the creation of the Group of Advisers on  the Ethical Implications of Biotechnology 
in  November 1991,  in  response  to  the  wishes  expressed  by  President  Jacques 
Delors.  Acting entirely autonomously,  this Group formulates  opinions designed to 
contribute to the Commission's policy-making work, including the legislative sphere. 
In its first term of office (1991-93), the Group produced a number of opinions either 
on  its  own  initiative  (patentability  of  biotechnological  inventions)  or  at  the 
Commission's request (marketing of SST and application of  the directive on products 
derived from human blood or plasma).  · 
The Group's next opinions will deal with prenatal diagnostics, transgenic animals and 
the labelling of new foodstuffs. 
For its  second  term  of office,  the  role  of the  Group  has  been  strengthened,  as 
provided for in the White Paper's recommendations. Mrs Noelle Lenoir, a lawyer and 
Chairwoman of the UNESCO International Committee on Bioethics, was elected to 
the Chair. 
The other eight leading personalities making up the Group are:  Dr Anne McLaren 
(GB, biologist), Dr Margareta Mikkelsen (OA,  geneticist), Professor Luis Archer (P, 
geneticist), Professor Gilbert Hottois (8, philosopher},  Professor Dietmar Mieth (D, 
philosopher/theologian), Mr Octavi Quintana-Trias (E, doctor of  medicine), Professor 
Stefano  Rodota  (I,  lawyer)  and  Professor  Egbert  Schroten  (NL, 
philosopher/theologian). 
INFOR,\\AClON .-\LA PRENSA  •  PRESSE  MEDDELCLSE  •  \\ITTEILL'~C -\N  DIE  PRESSE  • 
ANAKOINillH rtA TON n'nO  •  PRESS-RELE.\SE  •  INFt )R.\ 1,\  TIO~ -\  L.-\  PRESSE  • 
INFORN\A.ZIO~E -\LL.-\ ST,-\MP \  •  \\EDEOELt:"-iC  \.-\i'<  DE  ?!:i\.-:  • (:\ 1\\l  ~IC.-\D<) DE  1.\\PRE\iS-\ For the  first time,  the  Group will  present  one  of its  opinions  in  public at  a press 
conference on 13 December. This particular opinion is concerned with gene therapy. 
The new policy of openness reflects the desire for dialogue and the perceived need 
to move closer to the concerns of the people of Europe. 
Gene therapy  can  be  seen  as  the  introduction  of one  or  more  genes  within  an 
organism  by way  of a vector,  e.g.  a virus,  with  a view to  treating  or preventing  a 
disease linked to a genetic anomaly. This new therapeutic tool is based on progress 
made in the course of broadly-based research programmes within major international 
networks, e.g. the Community research  programme  on  Human Genome Analysis. 
Gene therapy is dubbed "somatic" where it is concerned with differentiated cells of 
the foetus, .the child or the adult (e.g.  cells of the liver,  blood or other organs),  and 
is referred to as "genninal" where it is concerned with  non-differentiated cells (e.g. 
gametes  or the  fertile  egg).  In  the  latter case,  the  genetic  modification  will  be 
transmitted to the individual's offspring. 
The future of gene therapy concerns a number of Community policy sectors,  more 
particularly public health (Article  129 of the Maastricht Treaty) and research,  under 
the fourth Framework Programme. 
Biotechnological experimentation  is  raising  enormous  hopes for the. treatment  of 
genetic diseases such  as  haemophilia,  and acquired diseases, such  as  cancer or 
cardiovascular disease or even AIDS.  Medicines developed via  gene therapy and 
which have reached the industrial stage will be submitted for testing by the European 
Agency for the Evaluation of Medicinal Products. 
Resources are undoubtedly needed if we are to live up to these expectations, but we 
also have to be responsive to the risks which are inherent in testing and even in the 
possible abuse of gene therapy practices. 
In its work, the Group of Advisers on the Ethical Implications of Biotechnology apply 
the following principal criteria:  protection of patient's rights and  respect for human 
dignity;  enhanced  evaluation  of  risks  and  results;  transparency  of  practices; 
surveillance of medical indications; equal access to new forms of treatment in terms 
of distributive justice; public information and education on democratic constraints. 
- 2-5.  Communique  de  presse  de  Ia  Commission eumpeenne  presentant 
l'avis sur Ia therapie genique. .. 
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Bruxelles, le  12 decembre 1994 
LE GROUPE DE CONSEILLERS POUR L'ETHIQUE DE  LA 
BIOTECHNOLOGIE  REND  PUBLIC  SON  AVIS  A  LA 
COMMIS$10~  EUROPEENNESUR LA THERAPIE GENIQUE 
Les remarquables avancees de Ia recherche scientifique et medicale de Ia seconde 
moitie de ce siecle ont ouvert Ia voie au developpement des biotechnologies.  Ces 
dernieres couvrent un large eventail de precedes dont les applications,  dans des 
domaines  allant  de  !'agriculture  a l'industrie,  de  l'environnement  a Ia  sante, 
interessent les divers secteurs de competence de Ia Communaute europeenne. 
C'est  Ia  raison  pour  laquelle,  en  decembre  1993,  le  Uvre  Blanc  sur le  theme 
"Croissance, competitivite et emploi" range le developpement des biotechnologies 
parmi les priorites de I'Europe. 
Si ces technologies suscitent des attentes, voire de t'enthousiasme, elles font parfois 
aussi naitre des craintes.  Maitriser ces progres en vue d'ameliorer Ia qualite et le 
niveau de vie des citoyens de I'Europe, et de leur assurer le niveau le plus eleve de 
sante dans le respect des valeurs de notre societe,  tel est le defi a  relever. 
La Commission est directement concemee par cet important debat.  La creation du 
Groupe de Conseillers pour I'Ethique de Ia Biotechnologie en novembre 199 1  . 
suivant les  voeux du  president Jacques  Delors,  se  situe  dans le  droit fil  de  ces 
preoccupations.  Se prononc;ant l!n toute independance, ce Groupe formula des avis 
qui contribuent a  orienter les actions de Ia Commission, y  compris dans le domaine 
legis  Iatif. 
Lors  de son  premier mandat (1991-1993),  le  Groupe a statue,  soit de sa  propre 
initiative (autosaisine sur Ia brevetabilite des inventions biotechnologiques), ·so it sur 
saisine  de  Ia  Commission  (concernant·  Ia  commercialisation  eventuelle  de  Ia 
somatotropine bovine et !'application de Ia directive sur les produits derives du sang 
ou du plasma humains). 
Les  prochains  avis  du  Groupe  traiteront  du  diagnostic  prenatal,  des  animaux 
transgeniques, et de l'etiquetage des nouveaux aliments. 
Le deuxieme mandata vu le re11forcement  du role du Groupe, conformement aux 
recommandations  du  Livre  Blanc.  Mme  Noelle  Lenoir,  juriste  et presidente  du 
Comite International de Bioethique de I'UNESCO en a ete elue presidente. 
Le Groupe est en outre, compose de huit personnalites eminentes: Dr Anne Mclaren 
(GB,  biologiste), Dr Margareta Mikkelsen (DA, geneticienne), Prof.  Luis Archer (P, 
geneticien), Prof. Gilbert Hottois (8, philosophe), Prof. Dietmar Mieth (0, philosophe 
theologian), M. Octavi Quintana-Trias (E, medecin), Prof. Stefano Rodota {1, juriste}, 
et Prof.  Egbert Schroten (NL, philosophe theologian)  . 
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ANAKOINillH riA TON lYnO  •  PRESS-RELEASE  •  INFORMATION A LA  PRESSE  • 
INFORMAZIONE ALLA STAMPA  • MEDEDEUNG AAN  DE  PERS  • COMUNICADO DE  IMPRENSA Pour Ia premiere fois, le Groupe rendra public lors d'une conference de presse le 13 
decembre un avis: celui sur Ia therapia genique. Cette nouvelle demarche traduit 
une volonte de dialogue et de rapprochement vers les preoccupations du citoyen de 
I' Europe. 
La therapia genique peut se definir comme l'introduction d'un ou plusieurs genes a 
l'interieur d'un organisme au moyen d'un vecteur, un virus par example, pour traiter 
ou  prevenir  une  maladie  liee  a une  anomalie  genetique.  Ce  nouvel  outil 
therapeutique resulte des progres accomplis dans le cadre de vastes programmes 
de recherche au  sein  de reseaux intemationaux importants,  comme  par exemple 
celui du programme de recherche Communautaire sur I'Analyse du Genome Humain. 
La  therapia  genique  est  appelee  "somatique"  quand  elle  vise  des  cellules 
differentiees  du  foetus,  de  l'enfant ou  de  l'adulte  (cellules  du  foie,  du  sang  ou 
d'autres  organes).  Elle  est  dite  "germinale"  lorsqu'elle  conceme  des  cellules 
indifferenciees (gametes ou oeuf feconde  ).  Dans ce cas, Ia modification genetique 
se transmettra a  Ia descendance de l'individu. 
L'avenir  de  Ia  therapia  genique  conceme  divers  champs  de  competence 
communautaires, notamment en matiere de sante publique (Article 129 du Traite de 
Maastricht) et de recherche dans Ia ligne du quatrieme programme-cadre. 
Cette pratique  experimentale  souleve  d'immenses  espoirs  dans le  traitement de 
maladies  genetiques,  telles  Ia  muscoviscidose  ou  l'hemophilie,  mais  aussi  de 
maladies acquises, comme le cancer ou les maladies cardio-vasculaires, voir meme 
le SIDA.  Les medicaments issus de Ia therapia genique qui auront atteint le stade 
industrial,  seront par ailleurs soumis a  Ia  procedure de I'Agence Europeenne des 
Medicaments. 
.• 
Des  moyens  sont  necessaires  pour  permettre  de  concretiser  les  espoirs  ainsi 
souleves.  M&is des reponses doivent aussi etre apportees compte tenu des risques 
inherents aux essais therapeutiques ou meme a  d'eventuelles utilisations abusives 
des pratiques. 
Pour  mener  sa  reflexion,  le  Groupe  de  Conseillers  pour  I'Ethique  de  Ia 
Biotechnologie se  fonde  notamment sur les criteres  suivants:  Ia  protection  des 
droits des patients concemes et le respect de Ia dignite humaine; l'amelioration de 
!'evaluation des risques et des resultats; Ia transparence des pratiques; le centrale 
des indications medicales; l'egalite d'acces aux nouveaux traitements dans le cadre 
de  Ia  justice  distributive;  !'information  et  l'education  du  public  au  regard  des 
necessites democratiques. 
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